Abstract. Recently, we demonstrated that radiolabelled interleukin-lo~ (IL-1) specifically accumulates in focal infection in mice through interaction with its receptor.
Introduction
The rather lengthy time required for infection localization with conventional nuclear medicine techniques [1, 2] has stimulated the search for new agents with better imaging properties. Small receptor binding peptides seem to be attractive candidates. Our previous study showed fast background clearance and good accumulation of radiolabelled interleukin-1 (IL-1) -a 17-kDa cytokine -in the infectious focus [3] . Extremely high abscess-to-background ratios were obtained and specific retention at the site of the infection was shown to be due to receptor binding.
Unfortunately, systemic side-effects of IL-1, such as fever and hypotension, hamper its clinical application [4] . These side-effects can occur at doses as low as 10 ng/kg. For these reasons, the potential of the naturally occurring IL-1 receptor antagonist (IL-ira) was studied. This equally sized molecule is structurally related to ILl and binds to the IL-1 receptor with similar high affinity, but does not initiate signal transduction, thus preventing any biological response [5] . Human studies have shown that patients injected with doses up to 10 mg/kg do not show any clinical signs and symptoms or changes in laboratory parameters [6] . Radiolabelled IL-lra therefore may be a potentially suitable imaging agent that can be applied clinically. In this study the in vitro and in vivo behaviour of radioiodinated IL-lra was compared with that of IL-1.
Materials and methods
by incubating it with 5 gg N-chlorosuccinimide for 10 rain at room temperature in methanol. The reaction was terminated by adding 5 #g Na2S205 to the reaction mixture. The methanol was evaporated with a gentle stream of N 2. Subsequently, 10 btg IL-1 or IL-lra in 2 btl 1.0 M bicarbonate buffer, pH 8.2, was added and incubated for 15 min on ice.
Following the labelling reaction, the reaction mixture was applied to a Sephadex G-75 (Pharmacia, Uppsala, Sweden) column (0.7x50 cm; Biorad, Hercules, Calif.) and eluted with 0.025% gelatine in Tris-HC1 buffer 1 mM EDTA pH 7.4 to separate labelled proteins from free lzsI. The void fractions were pooled and sterilized through a 0.2-gm filter (Millipore, Milford, Mass.). The radiochemical purity of the radiopharmaceuticals was determined as described [3] .
Radiolabelled IL-1 and IL-lra preparations were analysed by high-performance liquid chromatography (HPLC) before and after incubation in mouse serum for 4 h at 37°C in order to test the stability of the radiolabelled proteins. A Shodex protein KW-802.5 packed column with an MW range of 100-50 000 (8x300 mm; Millipore, Milford, Mass.) was used. Tris-HC1 buffer with 0.025% gelatine and 1 mM EDTA, pH 7.4, was used as the elution buffer. The flow rate was 0.5 ml/min.
Receptor binding assays
The murine cell line EL-4-6.1 [8] , a kind gift of Dr. H.R. MacDonald (Ludwig Institute for Cancer Research Epalinges, Switzerland), was cultured at 37°C in a humidified atmosphere of air/CO 2 (95:5) in RPMI 1640 medium (GIBCO, Gaithersburg, Md.) containing 10% foetal calf serum. The EL-4 binding assays and Scatchard analyses were performed as described previously
Competitive binding assay. Live EL-4-6.1 cells were incubated with 2x10 q° M 125I-IL-1 or 125I-IL-lra and respectively serially diluted unlabelled IL-lra or IL-I (10 13 10-6 34). After an incubation period of 4 h at 4°C, cell-bound radioactivity was separated from unbound 125I-IL-1 by centrifugation (5 min, 2000 g) and measured in the gamma counter.
Biodistribution experiments
Staphylococcus aureus abscesses were induced in the left calf muscles of ether-anaesthetized Swiss mice (20-30 g) as described previously [3] . Twenty-four hours after the inoculation of S. aureus in the muscle, when swelling of the muscle was apparent, either 0.4 MBq [25I-IL-1 or 0.4 MBq 125I-IL-lra was injected in the tail vein. Urine samples were analysed by HPLC 4 h after injection. Groups of five mice were killed under ether anaesthesia by cervical dislocation at 4, 12, 24 and 48 h after injection of the radiopharmaceuticals. Several organs were dissected, weighed and counted in the gamma counter. The measured activity was expressed as a percentage of injected dose per gram tissue (%ID/g).
Analogously, to study the effect of the biological activity of IL-1 on the receptor binding of lzsI-IL-lra in the infectious focus, 
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Statistical analysis
All values are expressed as mean _+ standard error of the mean (s.e.m.). Statistical analysis was performed using the one-way analysis of variance (ANOVA).
Results
Radiolabelling and characterization of the radiolabelIed proteins
The labelling efficiencies for both 125I-IL-1 and 125I-ILlra were in the range of 20%-30%. The specific activities of IzsI-IL-1 and 125I-IL-lra were 0.3-0.7 MBq/~tg. The radiochemical purity of all radiopharmaceuticals was higher than 95% after gel filtration. The preparation of radiolabelled IL-1 remained stable in mouse serum, as shown by the results of HPLC analyses before and 4 h after incubation of 125I-IL-1 in mouse serum at 37°C (Fig. 1A,C) . After 4 h, most of the radioiodine was still IL-1 bound. In contrast, the HPLC profiles of lzsI-IL-lra demonstrated a shift of radioactivity from 17 kDa to a higher molecular weight compound (>60 kDa) after 4 h incubation in mouse serum (Fig. 1B,D) . To investigate whether this shift could be attributed to either aggregation of IL-lra or association of 125I-IL-lra with serum proteins, 125I-IL-lra was incubated in phosphate-buffered saline (PBS) as well. Samples were analysed after 30 rain and 4 h incubation of the protein in PBS or mouse serum at 37°C. The shift to high molecular weight products could already be observed after 30 min in mouse serum. After 4 h, most of the radioactivity was found in the high molecular weight range. However, the shift to the high molecular weight compounds was not found when 125I-IL-lra was incubated in PBS (data not shown). The receptor binding fraction of both 125I-IL-1 and 125I-IL-lra for conditions representing infinite cell receptor excess was always between 60% and 75%. The non-specific binding was less than 5%. Scatchard analysis revealed that 125I-IL-1 and 125I-IL-lra bind to the ILl receptor on EL-4 cells with almost equal affinities, respectively 5.4x10 -11 and 4.7x10 11 mol/l. Furthermore, as shown by the results of the competitive binding assay (Fig. 2) , the binding of 125I-IL-1 to its receptor on the EL-4 cells could be completely inhibited by an excess of unlabelled IL-lra with an IC50 value of 3.5x10 10 mol/1. The inhibition of 125I-IL-lra by unlabelled IL-1 was equally efficient, with an IC50 value of 4.6x10 -1° mol/1.
Biodistribution experiments
Both radiolabelled IL-1 and IL-lra rapidly cleared from the blood and most other organs (Table 1) . After 4 h p.i., only 0.52_+0.04%ID/g and 0.98_+0.07%ID/g for 125I-IL-1 and 125I-IL-lra, respectively, was retained in circulation. Most of each of the radiolabelled proteins was excreted via the kidneys during the first hours after injection. Both proteins were mainly excreted in the urine as low molecular weight metabolites: 2.5-3.5 kDa as determined by the Rf values obtained from the HPLC profiles (data not shown).
Despite its rapid blood clearance, 125I-IL-1 was retained in the abscess at >0.6%ID/g from 4 h p.i. onwards. Although 125I-IL-lra cleared even somewhat slower from circulation, the retention in the abscess was 10 times lower (0.06%ID/g at 48 h p.i.) (Fig. 3) . At all time points, the abscess uptake of 125I-IL-lra was significantly lower than that of 125I-IL-1 (P<0.02).
Retention in the abscess of 125I-IL-1, and to a lesser extent of 125I-IL-lra, was demonstrated by increasing abscess-to-contralateral muscle ratios of both agents in the time course of the study (Fig. 4) . The abscess-tocontralateral muscle ratios of 125I-IL-1 increased from 3.8_+0.5 at 4 h p.i. to 46.9_+5.7 at 48 h p.i. The ratios of 125I-IL-lra increased to a significantly lower value of 15.5+2.9 at 48 h p.i. (P<0.005). Table 2 summarizes the biodistribution data of S. aureus-infected mice i.v. injected with a mixture of 125I-ILlra and unlabelled IL-1. The biodistribution data of 125I-IL-lra in these mice are highly similar to the data shown in Table 1 , when no unlabelled IL-1 was adminstered to the mice. The abscess uptake did not change significantly as a result of the co-injection of a small amount of unlabelled IL-1 during the time span of the study. fore, our results demonstrate that a receptor antagonist may not localize in infectious loci while its agonist is specifically retained at the site of inflammatory cells. There may be several possible explanations for the difference in abscess uptake of IL-1 and IL-lra. Firstly, since human recombinant IL-lra was injected in mice, species specificity may play a role. Human IL-lra is 76% identical to its murine counterpart [10] . The differences may be responsible for the low abscess uptake of 125I-IL-lra. Secondly, internalization of the radiolabelled protein after binding to its receptor on inflammatory cells may be essential for retention of the protein in the infection. Studies have shown that the majority of surface-bound 125I-IL-1 is internalized at 37°C within a few hours. It does not undergo degradation for at least 6 h after internalization [11] . However, in contrast to IL-1, surface-bound IL-lra does not undergo receptor-mediated internalization [5] . Finally, association of IL-lra with serum proteins in circulation -as demonstrated by HPLC analysis -may make it less available for IL-1 receptor binding in the infectious focus. This phenomenon was not observed for IL-1. Aggregation could be ruled out since most radioactivity was found at 17 kDa after 4 h incubation in PBS at 37°C.
Our study showed that the lack of biological activity of IL-lra does not explain the low retention in the inflammatory focus. The biological activity of IL-1, including a wide range of inflammatory and immunological effects, did not influence the abscess uptake of ILlra when unlabelled IL-1 was co-injected with radiolabelled IL-lra.
IL-lra could only be succesfully labelled by using the Bolton-Hunter method. Other radioiodination methods significantly reduced the receptor binding capability of IL-lra (data not shown). For comparison, IL-1 was also labelled according to the Bolton-Hunter method. We prefer to use the iodogen labelling method for radioiodination of IL-1 because of the higher labelling efficiency [3] . It appeared that the labelling method influenced the clearance of the radiolabelled protein. The Bolton-Hunter method resulted in faster blood clearance of radioiodinated IL-1 than did the iodogen method. Nevertheless, the retention in the abscess was similarly high, demonstrating that the binding of radiolabelled IL-1 to inflammatory cells already takes place in the initial hours postinjection. During the following hours, non-bound IL-1 will be removed from the tissues, while bound IL-1 is retained in the infection.
Discussion
This paper has described a direct comparison of radioiodinated IL-1 and its receptor antagonist in vitro and in vivo in an animal model of infection. Despite the highly similar in vitro characteristics of the two proteins, the in vivo behaviour was different. The retention of IL-lra in the abscess was 10 times lower than that of IL-1. There-
Conclusion
IL-lra could have been the ideal alternative to IL-1 to circumvent the toxicity of IL-1 and to use the receptor binding capacity for infection imaging. However, this study showed a significantly lower retention in the infection of IL-lra compared to IL-1. This may be caused by specific molecular properties of IL-lra, such as associa-tion with serum proteins in vivo, indicating that human recombinant IL-lra is less advantageous for imaging of infection and inflammation. Instead of looking at IL-lra, the development of a technetium-99m labelling method with high specific activity using IL-1 seems to be a more appropriate direction. Theoretically, when at least one 99mTc atom is incorporated per IL-1 molecule, very low amounts of protein (<10 ng/kg) which are nevertheless sufficient for imaging purposes can be injected in patients without causing any side-effects. Our future plans will focus on the development of 99mTc labelling of IL-1 with sufficiently high specific activity.
